Fig. 9From: The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in GermanySHI Willingness to Pay for absolute soloist orphan drugs. The willingness to pay of the Statutory Health Insurance for absolute soloist orphan drugs is depictedBack to article page